Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Overall Study	STARTED	Vedolizumab 300 mg (C13006)	675
Overall Study	STARTED	Vedolizumab 300 mg (C13007)	726
Overall Study	STARTED	Vedolizumab 300 mg (C13011)	384
Overall Study	STARTED	Vedolizumab 300 mg (C13004)	37
Overall Study	STARTED	Vedolizumab 300 mg (C13008 De Novo Participants)	421
Overall Study	COMPLETED	Vedolizumab 300 mg (C13006)	237
Overall Study	COMPLETED	Vedolizumab 300 mg (C13007)	246
Overall Study	COMPLETED	Vedolizumab 300 mg (C13011)	115
Overall Study	COMPLETED	Vedolizumab 300 mg (C13004)	23
Overall Study	COMPLETED	Vedolizumab 300 mg (C13008 De Novo Participants)	145
Overall Study	NOT COMPLETED	Vedolizumab 300 mg (C13006)	438
Overall Study	NOT COMPLETED	Vedolizumab 300 mg (C13007)	480
Overall Study	NOT COMPLETED	Vedolizumab 300 mg (C13011)	269
Overall Study	NOT COMPLETED	Vedolizumab 300 mg (C13004)	14
Overall Study	NOT COMPLETED	Vedolizumab 300 mg (C13008 De Novo Participants)	276

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00790933/flow